Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, Japan.
Radiother Oncol. 2017 Mar;122(3):368-372. doi: 10.1016/j.radonc.2016.12.020. Epub 2017 Jan 3.
To clarify the efficacy and feasibility of proton beam therapy (PBT) for olfactory neuroblastoma (ONB).
We retrospectively reviewed 42 consecutive patients who received PBT with curative intent for ONB at National Cancer Center Hospital East from November 1999 to March 2012.
Five patients (12%) had Kadish A disease, nine (21%) had Kadish B, and twenty-eight (67%) had Kadish C. All patients except one received a total dose of 65Gy (relative biological effectiveness: RBE) in 26 fractions. Twenty-four patients (57%) received induction and/or concurrent chemotherapy. The median follow-up for all eligible patients was 69months (7-186). The 5-year overall survival (OS) and progression-free survival (PFS) rates were 100% and 80% for Kadish A, 86 and 65% for Kadish B, and 76% and 39% for Kadish C, respectively. The sites of the first progression were local in six patients (30%), regional in eight (40%), distant in two (10%), local and regional in two (10%), and local and distant in two (10%). Late adverse events of grade 3-4 were seen in six patients (ipsilateral visual impairment, 3; bilateral visual impairment, 1; liquorrhea, 1; cataract, 1).
PBT was a safe and effective modality for ONB.
阐明质子束治疗（PBT）治疗嗅神经母细胞瘤（ONB）的疗效和可行性。
我们回顾性分析了 1999 年 11 月至 2012 年 3 月在国立癌症中心医院东院接受根治性 PBT 治疗的 42 例连续 ONB 患者。
5 例（12%）患者为 Kadish A 期，9 例（21%）为 Kadish B 期，28 例（67%）为 Kadish C 期。除 1 例外，所有患者均接受 26 次分割 65Gy 的总剂量（相对生物学效应：RBE）。24 例（57%）患者接受诱导和/或同期化疗。所有合格患者的中位随访时间为 69 个月（7-186）。Kadish A 期的 5 年总生存率（OS）和无进展生存率（PFS）分别为 100%和 80%，Kadish B 期分别为 86%和 65%，Kadish C 期分别为 76%和 39%。6 例（30%）患者的首次进展部位为局部，8 例（40%）为局部区域，2 例（10%）为远处，2 例（10%）为局部和区域，2 例（10%）为局部和远处。6 例（同侧视力障碍 3 例，双侧视力障碍 1 例，脑脊液漏 1 例，白内障 1 例）出现 3-4 级迟发性不良事件。
PBT 是治疗 ONB 的一种安全有效的方法。
